Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Keenova Therapeutics plc from 25 Sep 2015 to 28 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Keenova Therapeutics plc quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 25 Sep 2015 to 28 Mar 2025.
  • Keenova Therapeutics plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 28 Mar 2025 was $40,000,000.
  • Keenova Therapeutics plc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $102,300,000.
  • Keenova Therapeutics plc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2021 was $278,200,000, a 8.6% decline from 2020.
  • Keenova Therapeutics plc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2020 was $304,400,000, a 33% decline from 2019.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

Keenova Therapeutics plc Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $40,000,000 +$51,900,000 28 Dec 2024 28 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $11,900,000 -$82,100,000 -117% 30 Dec 2023 29 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $70,000,000 15 Nov 2023 29 Dec 2023 10-K 13 Mar 2025 2024 FY
Q1 2023 $70,200,000 +$49,700,000 +242% 31 Dec 2022 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $47,900,000 17 Jun 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $43,900,000 17 Jun 2022 01 Jul 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $20,500,000 +$10,000,000 +95% 01 Jan 2022 01 Apr 2022 10-Q 09 May 2023 2023 Q1
Q1 2021 $10,500,000 -$16,100,000 -61% 26 Dec 2020 26 Mar 2021 10-Q 03 May 2022 2022 Q1
Q1 2020 $26,600,000 +$149,600,000 28 Dec 2019 27 Mar 2020 10-Q 04 May 2021 2021 Q1
Q1 2019 $123,000,000 +$625,900,000 +84% 29 Dec 2018 29 Mar 2019 10-Q 06 May 2020 2020 Q1
Q1 2018 $748,900,000 30 Dec 2017 30 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2016 $61,500,000 -$94,300,000 -61% 01 Oct 2016 30 Dec 2016 10-K 26 Feb 2019 2018 FY
Q4 2015 $155,800,000 26 Sep 2015 25 Dec 2015 10-K 26 Feb 2019 2018 FY

Keenova Therapeutics plc Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $102,300,000 30 Dec 2023 27 Dec 2024 10-K 13 Mar 2025 2024 FY
2021 $278,200,000 -$26,200,000 -8.6% 26 Dec 2020 31 Dec 2021 10-K 26 Mar 2024 2023 FY
2020 $304,400,000 -$150,700,000 -33% 28 Dec 2019 25 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 $455,100,000 +$1,366,700,000 29 Dec 2018 27 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $911,600,000 -$1,829,600,000 -199% 30 Dec 2017 28 Dec 2018 10-K 10 Mar 2021 2020 FY
2017 $918,000,000 +$1,051,000,000 31 Dec 2016 29 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $133,000,000 +$212,000,000 +61% 26 Sep 2015 30 Sep 2016 10-K 26 Feb 2019 2018 FY
2015 $345,000,000 27 Sep 2014 25 Sep 2015 10-K 27 Feb 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.